Literature DB >> 11257047

In vitro and in vivo combinations of cefotaxime and minocycline against Aeromonas hydrophila.

W C Ko1, H C Lee, Y C Chuang, S H Ten, C Y Su, J J Wu.   

Abstract

The activities of cefotaxime and minocycline against Aeromonas hydrophila were investigated. Cefotaxime (4 times the MIC) plus minocycline (0.75 times the MIC) elicited an inhibitory effect for 48 h in a time-kill study, and more infected mice treated with both drugs survived (91%) than survived after treatment with cefotaxime (9%) or minocycline (44%) alone, suggesting that cefotaxime and minocycline act synergistically against A. hydrophila.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11257047      PMCID： PMC90456          DOI： 10.1128/AAC.45.4.1281-1283.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Distribution and expression of beta-lactamase genes among Aeromonas spp.

Authors:  T R Walsh; R A Stunt; J A Nabi; A P MacGowan; P M Bennett
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

2.  Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia.

Authors:  W C Ko; H C Lee; Y C Chuang; C C Liu; J J Wu
Journal:  J Infect       Date:  2000-05       Impact factor: 6.072

3.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

4.  In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus.

Authors:  Y C Chuang; J W Liu; W C Ko; K Y Lin; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

5.  Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.

Authors:  Y C Chuang; W C Ko; S T Wang; J W Liu; C F Kuo; J J Wu; K Y Huang
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  Inducible beta-lactam resistance in Aeromonas hydrophila: therapeutic challenge for antimicrobial therapy.

Authors:  W C Ko; H M Wu; T C Chang; J J Yan; J J Wu
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

7.  Aeromonas species in septicemia: laboratory characteristics and clinical observations.

Authors:  J M Janda; L S Guthertz; R P Kokka; T Shimada
Journal:  Clin Infect Dis       Date:  1994-07       Impact factor: 9.079

8.  Inhibition of beta-lactamase synthesis in Staphylococcus aureus by minocycline.

Authors:  I Chopra; M A Anderson
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

9.  Aeromonas septicaemia in Hong Kong species distribution and associated disease.

Authors:  R Duthie; T W Ling; A F Cheng; G L French
Journal:  J Infect       Date:  1995-05       Impact factor: 6.072

10.  Aeromonas bacteremia: review of 59 episodes.

Authors:  W C Ko; Y C Chuang
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079
View more
  4 in total

1.  In Vitro Synergy and In Vivo Activity of Tigecycline-Ciprofloxacin Combination Therapy against Vibrio vulnificus Sepsis.

Authors:  Seong Eun Kim; Hee Kyung Kim; Su-Mi Choi; Yohan Yu; Uh Jin Kim; Kalifa Sanneh Darboe; Seung-Ji Kang; Kyung-Hwa Park; Gaeun Kang; Young Ran Kim; Joon Haeng Rhee; Sook-In Jung; Hee-Chang Jang
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.

Authors:  Wen-Chien Ko; Shyh-Ren Chiang; Hsin-Chun Lee; Hung-Jen Tang; Yin-Yi Wang; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 3.  Emerging Aeromonas species infections and their significance in public health.

Authors:  Isoken H Igbinosa; Ehimario U Igumbor; Farhad Aghdasi; Mvuyo Tom; Anthony I Okoh
Journal:  ScientificWorldJournal       Date:  2012-06-04

4.  In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia.

Authors:  Nam Su Ku; Su-Hyung Lee; Young- Soun Lim; Heun Choi; Jin Young Ahn; Su Jin Jeong; Sung Jae Shin; Jun Yong Choi; Young Hwa Choi; Joon-Sup Yeom; Dongeun Yong; Young Goo Song; June Myung Kim
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.